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A B S T R A C T
Uveal melanoma is an aggressive malignancy that originates from melanocytes in the eye. Even if the primary tumor has been successfully treated with radiation or
surgery, up to half of all UM patients will eventually develop metastatic disease. Despite the common origin from neural crest-derived cells, uveal and cutaneous
melanoma have few overlapping genetic signatures and uveal melanoma has been shown to have a lower mutational burden. As a consequence, many therapies that
have proven effective in cutaneous melanoma -such as immunotherapy- have little or no success in uveal melanoma. Several independent studies have recently
identified the underlying genetic aberrancies in uveal melanoma, which allow improved tumor classification and prognostication of metastatic disease. In most cases,
activating mutations in the Gα11/Q pathway drive uveal melanoma oncogenesis, whereas mutations in the BAP1, SF3B1 or EIF1AX genes predict progression
towards metastasis. Intriguingly, the composition of chromosomal anomalies of chromosome 3, 6 and 8, shown to correlate with an adverse outcome, are distinctive
in the BAP1mut, SF3B1mut and EIF1AXmut uveal melanoma subtypes. Expression profiling and epigenetic studies underline this subdivision in high-, intermediate-, or
low-metastatic risk subgroups and suggest a different approach in the future towards prevention and/or treatment based on the specific mutation present in the
tumor of the patients. In this review we discuss the current knowledge of the underlying genetic events that lead to uveal melanoma, their implication for the disease
course and prognosis, as well as the therapeutic possibilities that arise from targeting these different aberrant pathways.
1. Introduction
Uveal melanoma (UM) is the second most common form of mela-
noma, arising from melanocytes located in the uveal tract of the eye. It
is a highly aggressive disease, with a strong tendency to metastasize
from the eye to other organs, such as the liver. The primary tumor can
be treated successfully using several options, such as enucleation, ste-
reotactic radiotherapy, brachytherapy and proton therapy (Damato,
2018; Singh et al., 2011). At the time of diagnosis of the primary tumor,
only 4% of patients show detectable metastases; however, up to half of
all UM patients will eventually develop metastatic disease despite
earlier successful local treatment of the primary tumor. This implies
that UM already develops micro-metastases early during tumorigenesis
and that these micro-metastases may remain dormant for several
months or even years (Eskelin et al., 2000). Once these micro-metas-
tases become overt, the prognosis is poor and disease-related death
usually occurs within one year (Augsburger et al., 2009). Metastases are
often detected within a few years after diagnosis, but they can also be
observed several decades after the initial diagnosis (Coupland et al.,
1996; Singh et al., 2004; Zimmerman et al., 1978). In general, UM can
be subdivided into three metastatic risk groups: high, intermediate and
low risk.
Several clinical and histological features can predict high metastatic
risk, such as large tumor size, extraocular extension, high mitotic ac-
tivity and an epithelioid cell type, whereas the spindle cell type is as-
sociated with low metastatic risk (Fig. 1) (McLean et al., 1982; Shields
et al., 2009; Yavuzyigitoglu et al., 2016a). Genetic features associated
with metastatic disease include loss of chromosome 3 and mutations in
the BAP1 and SF3B1 gene. BRCA-associated protein 1 (BAP1) mutations
are observed in approximately half of all UM and usually result in
metastasis within 5 years (Harbour et al., 2010). Our group has shown
that tumors with an SF3B1 mutation also frequently metastasize, but
this can take up to 15 years and these tumors are therefore considered
to have an intermediate metastatic risk (Yavuzyigitoglu et al., 2016b).
UM that harbor a mutation in the EIF1AX gene seldom metastasize
(Martin et al., 2013). None of the 45 UM patients in our cohort with
only an EIF1AX mutation developed metastasis.
Recurrent chromosomal alterations are frequently observed in UM
and the majority occur in the context of a specific mutation. Most of the
BAP1-mutated UM show loss of chromosome 3, as well as gain of 8q.
Tumors with a mutation in the EIF1AX or SF3B1 gene often show gain
of chromosome 6p (Yavuzyigitoglu et al., 2017). Since there is little
heterogeneity in UM, it is likely that although these mutational and
chromosomal events can occur sequentially, both are mandatory in the
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development of UM to result in tumor growth (Field et al., 2018).
Downstream mRNA expression can also be determined to predict me-
tastatic risk. As previously described by Onken et al., UM patients can
be classified into a low or high metastatic risk group based on the ex-
pression profile of 15 genes (Onken et al., 2004). These two groups are
known as class 1 and class 2, with class 2 having the worst prognosis;
class 1 can be divided into 1a and 1b. A more recent subdivision which
is based on chromosomal data from The Cancer Genome Atlas
(Robertson et al., 2017), separates the tumors into categories A-D
(Jager et al., 2018).
Despite extensive research, the survival of metastasized UM patients
did not improve over the last three decades (Singh et al., 2011).
Whereas treatments such as immunotherapy and BRAF-inhibitors show
promising results in patients with cutaneous melanoma (CM), UM seem
to be unresponsive despite their shared origin as neural-crest derived
melanocytes. This indicates that different mechanisms play a role in
tumorigenesis. Oncogenic mutations in BRAF and NRAS are the main
drivers in CM, but these mutations have only been found in iris mela-
noma and do not occur in posterior UM (Rimoldi et al., 2003; van
Poppelen et al., 2018). Most CM (80%) exhibit a mutational signature
specific to DNA damage caused by ultraviolet radiation, characterized
by C>T transitions at the 3′ end of pyrimidine dinucleotides. Even
though population studies suggest a geographic predisposition, there is
no molecular evidence for this signature in UM (Robertson et al., 2017).
UM has a remarkably low mutational burden; with a rate of< 1 single
nucleotide variations (SNVs) per Mb, this mutation burden is much
lower than observed in most cancer types. Only 35% of the observed
SNVs in UM are C>T transitions and there is no enrichment of these
lesions at the 3’ position of pyrimidine dinucleotides, further showing
that CM and UM have a different etiology (Furney et al., 2013). So far,
UM clinical trials have focused on treatment modalities copied from
CM. However, despite these therapeutic options, the prognosis of pa-
tients with metastatic UM has not improved, which emphasizes the
need to explore and develop UM-specific therapies. In this review, we
highlight several scientific findings and studies that provide us with
insight into the mechanisms of oncogenesis of GNAQ, GNA11, BAP1,
SF3B1 and EIF1AX mutations. Elucidating the development of UM and
obtaining a better understanding of the complex interaction between
genetic factors, molecular signaling and potential targets will aid in
developing new therapies specific for UM.
2. Genes involved in the development of UM
An updated mutational overview of our previously published ROMS
cohort containing over 900 UM patients, shows initiating hotspot mu-
tations in GNAQ in 57% of the UM tumors and in GNA11 in 41%
(Fig. 2A) (Yavuzyigitoglu et al., 2016b). Samples that do not contain a
GNAQ or GNA11 mutation are usually found to harbor a mutation in
another gene linked to the Gα11/Q pathway: PLCB4 and CYSTLR2.
GNAQ and GNA11 mutations are already observed in most nevi (Vader
et al., 2017). In addition, in UM, one can often discern a mutation in
one of the three secondary driver genes (BAP1, SF3B1, EIF1AX): forty-
four percent of our 175 UM samples showed a BAP1 mutation, 26% a
mutation in SF3B1 and 21% a mutation in EIF1AX. We and others have
noticed that even with next generation sequencing (NGS) technology
mutations in BAP1, especially deletions encompassing whole exons, can
be missed and more sophisticated calling algorithms, in combination
with RNA sequencing have to be applied to detect these BAP1 muta-
tions (Field et al., 2018). We are using a combined BAP1-im-
munohistochemistry (IHC) and targeted NGS approach which is also
suitable for small biopsies and formalin-fixed, paraffin-embedded
(FFPE) tissue samples (Smit et al., 2018). The BAP1 gene acts as a
classic tumor-suppressor gene and in combination with loss of chro-
mosome 3, no active nuclear BAP1 protein is present in the tumor cells
(Farquhar et al., 2018). Missense mutations in SF3B1 or indels in
EIF1AX mutations are in-frame and create a small change in the re-
spective proteins, albeit with a large effect on many cellular RNAs and
proteins (Martin et al., 2013). Missense mutations in SF3B1 usually
arise at amino acid R625, a UM hotspot; however, some samples also
show mutations outside this hotspot region, such as at amino acids
K666 or H662 or in related spliceosome complex genes as SRSF2 and
U2AF1 (Robertson et al., 2017). Although not actually a hotspot,
EIF1AX in-frame mutations are located in the first 10–15 AA of this
gene which limits the region to be analyzed. A complicating factor in
NGS analysis is the closely-related pseudogene EIF1AXP1 on
Fig. 1. The fundoscopic and histologic appear-
ance of UM. A) A dome-shaped pigmented mass in
the posterior pole. B) Hematoxylin-eosin (HE)
staining shows that the tumor consists of spindle-
type UM cells and several adipocytic appearing cells
(100x). Reproduced with permission from
Yavuzyigitoglu et al. (2016a), via Copyright Clear-
ance Center.
Fig. 2. Driver mutations in UM. A) Donut chart showing the mutation status
of 165 UM patients of the ROMS cohort. The outer ring shows initiating mu-
tations in GNAQ, GNA11, PLCB4 and CYSTLR. The inner ring indicates co-
mutations in BAP1, SF3B1 or EIF1AX. The black dots indicate SF3B1 Q625
hotspot mutations B) The mutation rate of each gene observed in our study and
other studies. Adapted from (Yavuzyigitoglu et al., 2016b).
K.N. Smit, et al. Progress in Retinal and Eye Research xxx (xxxx) xxxx
2
chromosome 1. When possible, we use a SNP array to detect chromo-
somal aberrations to confirm the UM subclass. Our results and the ob-
served percentages do not deviate substantially from previously ob-
served mutation rates (Fig. 2B) (Dono et al., 2014; Ewens et al., 2014;
Harbour et al., 2010, 2013; Martin et al., 2013; Van Raamsdonk et al.,
2009, 2010; Yavuzyigitoglu et al., 2016b). The secondary mutations are
in general mutually exclusive, although 1–2% of the tumors did harbor
(hotspot) mutations in two of these metastasis-associated genes. In
these latter cases it would be interesting to see whether these mutations
arise in the same cells.
2.1. Activation of the Gα11/Q pathway drives neoplastic growth of uveal
melanocytes
The first gene reported to be mutated in UM was the guanine nu-
cleotide-binding protein alpha Q (GNAQ) gene (Van Raamsdonk et al.,
2009). Most of the UM samples that do not harbor a mutation in GNAQ
carry a mutation in its paralogue GNA11 (Van Raamsdonk et al., 2010).
Both proteins are involved in the Gα11/Q pathway, which regulates
several cellular processes such as proliferation and cell growth. In this
pathway, leukotrienes activate the G protein-coupled receptor
CYSTLR2 located at the cell surface. Guanine nucleotide-binding pro-
teins (G-proteins) consist of three subunits: alpha, beta and gamma.
GNAQ and GNA11 are alpha subunits (Gα) bound to a guanosine di-
phosphate (GDP). Upon binding of the ligand to CYSTLR2, G proteins
are activated by exchanging GDP for guanosine triphosphate (GTP)
(O'Hayre et al., 2013). GTP binding initiates a conformation change in
the G-protein, which allows the G protein to be released from the
CYSTLR2 receptor and to activate a large number of downstream ef-
fectors, such as PLCB4 and ARF6 (Moore et al., 2018; Yoo et al., 2016)
(Fig. 3).
Activation of ADP-ribosylation factor 6 (ARF6) by GNAQ or GNA11
initiates several processes, such as β-catenin release from the cytoplasm
to the nucleus and activation of the growth-inducing gene YAP1 (Feng
et al., 2014). YAP1 is critical for growth and is therefore often found in
the nucleus of proliferating cells. Inhibiting YAP1 strongly limits the
proliferation of UM cells (Feng et al., 2014; Yu et al., 2014a). Activated
PLCB4 causes a rise in cytoplasmic Ca2+, thereby activating several
calcium-regulated pathways (Griner and Kazanietz, 2007). PLCB4 also
indirectly activates the mitogen-activated protein kinase (MAPK) and
AKT/mTOR pathway through the downstream effector RasGRP3 (Chen
et al., 2017; Moore et al., 2018). MAPK and AKT/mTOR promote cell
growth and proliferation and are often upregulated in cancer.
Over 95% of the UM contain a mutually exclusive mutation in
GNAQ or GNA11. Mutations in GNAQ and GNA11 affect residues Q209
and R183, which are required for the GTPase activity (Van Raamsdonk
et al., 2009, 2010). In non-malignant cells, this activation is in-
trinsically terminated by a guanosine triphosphate (GTPase); oncogenic
GNAQ or GNA11 on the other hand are constitutively activated and
therefore result in over-activation of the aforementioned signaling
pathways. UM that do not harbor a mutation in GNAQ or GNA11
usually have a somatic mutation in CYSTLR2 (3%) or PLCB4 (2%)
(Johansson et al., 2016; Moore et al., 2016). Wildtype CYSTLR re-
ceptors become active after binding of the ligand and transition to the
inactivated state is initiated upon release of the ligand. However, mu-
tated receptors stay active even after ligand dissociation and thereby
constitutively activate GNAQ and GNA11 (Moore et al., 2016). This
confirms the requirement of aberrant Gα11/Q signaling in the devel-
opment of UM.
Introducing GNAQ and GNA11 mutations (Q209L) in zebrafish re-
sults in increased proliferation, signaling and migration (Perez et al.,
2018). However, most UM carry a GNAQ and GNA11 mutation re-
gardless of their tumor stage. This suggests that GNAQ and GNA11
mutations are necessary to initiate tumorigenesis, but are insufficient to
induce full malignant transformation, as is also shown by our finding
that these mutations are also present in nevi (Vader et al., 2017). The
aggressiveness of UM is determined by secondary driver mutations but
treatments targeting oncogenic GNAQ and GNA11 signaling or one of
their many downstream targets might reduce the proliferative potential
of UM and can therefore be promising for future therapy modalities as
will be discussed later in this review.
2.2. Loss of BAP1 is linked to metastatic UM
The majority of the metastasizing UM harbor -in addition to a GNAQ
or GNA11 mutation- a mutation in the BAP1 gene located on chromo-
some 3 (Harbour et al., 2010). We and others observed, using im-
munohistochemical analysis, (partial) loss of the BAP1 protein in BAP1-
Fig. 3. Schematic overview of the Gα11/Q
pathway and their downstream effectors.
Activated GNAQ binds to a guanine nucleotide ex-
change factor (GEF), which in turn activates ARF6.
ARF6 initiates β-catenin release, which promotes
gene transcription (Grossmann et al., 2013). GNAQ
and GNA11 can also activate the protein TRIO and
the TRIO dependent RHO-GTPases; RHOA and
RAC1. Once activated, RHO and RAC1 trigger the
release of YAP and stimulate YAP-dependent tran-
scription. ARF6 also activates PCLB4 which initiates
hydrolysis of phosphatidylinositol 4,5-biphosphate
(PIP2) and produces 2 s messengers; inositol 1,4,5-
triphosphate (IP3) and diacylglycerol (DAG). The
production of IP3 causes a rise in cytoplasmic
Ca2+, which stimulates several calcium-regulated
pathways. With the help of DAG, protein kinase C
(PKC) is activated and subsequently stimulates
several processes, such as cell proliferation. DAG
and PKC together also activate RAS guanyl-re-
leasing protein 3 (RASGRP3), by binding and
phosphorylation. RASGRPR3 is a GEF, that in-
tegrates GNAQ and GNA11 to the MAPK- and PI3K/
AKT pathway by activating RAS. GEFs stimulate the
release of GDP and the subsequent binding of GTP,
thereby yielding active RAS (RAS-GTP) (Chen et al.,
2017; Moore et al., 2018; Yoo et al., 2016; Yu et al.,
2014a,b,c; Feng et al., 2014).
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mutated UM (Fig. 4) (Kalirai et al., 2014; Koopmans et al., 2014; Shah
et al., 2013; Stalhammar et al., 2019a; Szalai et al., 2018). Other studies
show that loss of BAP1 staining is strongly correlated to GEP class 2 and
chromosome 3 loss and that loss of BAP1 protein expression is often
associated with lower BAP1 mRNA expression (van Essen et al., 2014).
This implies that these mutations are loss-of-function mutations, re-
quiring the loss of the other allelic copy harboring the wildtype gene
(monosomy 3). Surprisingly, some BAP1-mutated/im-
munohistochemically BAP1-negative tumors still show expression of
BAP1 mRNA, suggesting that negative nuclear staining for BAP1 pro-
tein is not solely caused by nonsense-mediated RNA decay but rather by
an as yet unexplained different mechanism (unpublished data). Muta-
tions in BAP1 are found throughout the entire gene and are not re-
stricted to a specific domain, although we did observe a skewed dis-
tribution towards the N-terminal region (Fig. 5) (Koopmans et al.,
2014). In the ROMS cohort, we observed a large variety of mutations,
such as large out-of-frame deletions, but also missense mutations. In a
preliminary analysis we did not find a significant association between
mutation-type or location with disease-free survival.
Despite extensive research exploring the function of the BAP1 pro-
tein, it is as yet unclear how BAP1 loss in UM promotes the develop-
ment of UM metastasis. BAP1 belongs to a specific group of proteases,
called deubiquitinating enzymes (DUB), which function as a critical
regulator of ubiquitin signaling by removing ubiquitin from proteins.
Initially, BAP1 was identified because of its interaction with breast
cancer 1 (BRCA1), a tumor suppressor gene involved in homology di-
rected DNA-repair. The absence of BAP1 inhibits homology directed
DNA-repair and thereby forces cells to rely on the more error-prone
non-homologous end joining (NHEJ) (Yu et al., 2014c). Surprisingly,
the mutational load in UM is significantly lower than in other cancer
types, suggesting that BAP1 loss in UM does not heavily impair DNA-
damage repair mechanisms. Other proteins that interact more fre-
quently with BAP1 could therefore be a more interesting target.
Some new proteins identified in these studies as interactors with
BAP1 are the forkhead transcription factors FOXK1 and FOXK2, the
histone acetyltransferase HAT1, the histone lysine demethylase
KDMB1B, the polycomb group proteins ASXL1 and ASXL2, host cell
factor C1 HCF1, and the ubiquitin-conjugated enzyme UBE20 (Ji et al.,
2014; Machida et al., 2009; Mashtalir et al., 2014; Peng et al., 2018;
Sowa et al., 2009; Yu et al., 2010). Most of these proteins are involved
in the regulation of chromatin-associated processes such as transcrip-
tion. This large number of interacting proteins implicates that absence
of BAP1 can have a plethora of downstream effects.
One protein that predominantly interacts with BAP1 is HCF1, a
protein involved in regulating the cellular localization of BAP1 through
the formation of multiprotein complexes with transcription factors such
as Yin Yang 1 (YY1) and FOXK1/2 (Dey et al., 2012; Yu et al., 2010).
HCF1 plays an important role in stem cell maintenance by regulating
genes involved in RNA processing and the cell cycle (Machida et al.,
2009). RNAi-mediated depletion of BAP1 expression triggered a pri-
mitive, stem-like phenotype in UM cells. Genes involved in the main-
tenance of stem cells and developmental processes were upregulated
and melanocyte-specific genes, such as MITF, were downregulated
(Matatall et al., 2013). Thus, loss of BAP1 dysregulates transcriptional
programs which are essential in the maintenance of the differentiated
melanocytic phenotype. The acquisition of a stem cell like-phenotype is
a common event in cells undergoing the epithelial-to-mesenchymal
(EMT) transition required for metastasis. EMT programming may con-
tribute to the highly metastasizing potential of BAP1-mutated UM cells
by enabling cells to physically disseminate from the primary tumor. It
also provides cells with the self-renewal capability that is crucial for
clonal expansion at the site of dissemination (Mani et al., 2008).
The interaction of BAP1 with ASXL1 and ASXL2, important catalytic
subunits of the polycomb repressive deubiquitinase (PR-DUB) complex,
could influence the regulation of homeobox genes by deubiquitinating
histone H2A (Chittock et al., 2017; Scheuermann et al., 2010). Histone
H2A plays a role in several cellular processes, such as stem cell main-
tenance and cell proliferation (Bommi et al., 2010). The ubiquitination
of histones alters the chromatin structure and thereby regulates the
accessibility of the DNA for the transcriptional machinery (van
Leeuwen and van Steensel, 2005). Knock down of BAP1 by RNA in-
terference induced an increase in H2A ubiquitination in UM cells, im-
plying that H2A ubiquitination might be an interesting therapeutic
target in high-risk UM.
Besides the aforementioned nuclear roles of BAP1, it also plays a
role outside the nucleus. BAP1 can be localized in the endoplasmic
reticulum (ER), where it stabilizes the type 3 inositol-1,4,5-triphosphate
receptor (IP3R3). IP3R3 is involved in promoting apoptosis by tightly
regulating the release of Ca2+ from the ER into the cytosol. Loss of
BAP1 reduces the amount of stable IP3R3, resulting in reduction of
Ca2+ influx and thereby preventing cell apoptosis (Bononi et al., 2017).
However, recent work from Farquhar et al. questioned the role of cy-
toplasmic BAP1 in the metastasis of UM, since they did not find a
correlation between disease-free survival of UM patients and the cyto-
plasmic expression of BAP1 (Farquhar et al., 2018; Szalai et al., 2018).
Fig. 4. BAP1-stained sections from three UM.
Immunohistochemistry (IHC) staining of BAP1
protein (red) in A) A UM with positive BAP1
expression B) A UM with negative BAP1 ex-
pression and C) A UM showing a heterogeneous
distribution of BAP1 throughout the tumor
(400x). Reproduced with permission from:
Koopmans et al. (2014).
Fig. 5. Overview of the BAP1 protein and its functional and interacting
domains. The BAP1 mutations we observe in our ROMS cohort are depicted
below the protein and classified according to their mutation type and location.
The N-terminal UCH domain ranges from amino acid 1–250, the HCF1-binding
domain (HMB)-like motif from amino acid 363–366, the UCH37-like domain
(ULD) from 634–396 and the two nuclear-localization signaling (NLS) from
amino acid 656–661 and 717–722. BAP1 also shows binding domains for
BARD1, HCFC1, BRCA1 and YY1. The binding site of the BAP1 IHC antibody is
indicated with the dashed line. Reproduced with permission from: Koopmans
et al. (2014).
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This large number of potentially relevant proteins makes it difficult
to determine the exact function of BAP1 due to the complex interaction
networks. BAP1 assembles into a multiprotein complex, which contains
several transcription- and co-factors. It is not clear yet which of these
many transcription factors plays the crucial role in the metastasis of
UM, showing that additional research regarding BAP1 in UM is neces-
sary. For this, it is interesting to study the outliers in the BAP1-mutated
group. For example, in our cohort we observed seven patients with
BAP1-mutated tumors who remained metastasis-free for over 10 years.
It has also been described that patients who carry a germline BAP1
mutation do not have a substantially earlier age-of-onset of UM than
other UM patients (Walpole et al., 2018). Additionally, these UM pa-
tients with germline mutations in BAP1 have a better prognosis than
patients with somatic mutations in BAP1. This suggests that in these
patients, mechanism(s) have developed that could temporarily coun-
teract the metastasis-promoting effect of BAP1 loss. Elucidating which
mechanisms would be capable of doing that will contribute sig-
nificantly to the development of a therapy targeted against BAP1 loss in
UM.
2.3. SF3B1 mutations result in aberrantly spliced mRNA
Metastasizing UM that do not show a BAP1 mutation often harbor a
mutation in the gene SF3B1 (Furney et al., 2013; Harbour et al., 2013;
Martin et al., 2013; Yavuzyigitoglu et al., 2016b). SF3B1 encodes sub-
unit 1 of the splicing factor 3b, which is responsible for proper
branchpoint recognition during splicing of pre-mRNA. Correct RNA
splicing is crucial for cell survival and allows cells to produce multiple
proteins from one single gene. Somatic mutations in components of the
spliceosome have been observed in several malignancies, such as
breast, pancreatic and hematologic cancers (Bailey et al., 2016; Ciriello
et al., 2015; Wang et al., 2011). The prevalence of cancer-associated
mutations in spliceosome genes suggests that dysregulation of splicing
can efficiently lead to the development of cancer.
SF3B1 mutations can result in aberrant splicing and it has been
shown that these mutations in UM result in alternative splicing at the 3’
end of exon borders (Alsafadi et al., 2016). These aberrantly spliced
transcripts can be degraded by nonsense-mediated RNA decay, re-
sulting in a loss of expression, but they can also be translated into un-
ique, aberrant proteins (Paolella et al., 2017) (Fig. 6). Several genes
have been shown to be affected in UM, such as ubiquinol-cytochrome C
reductase complex chaperone (UQCC) and the multidrug resistance-
associated protein ABCC5 (Furney et al., 2013).
The SF3B1 protein consists of an N-terminal hydrophilic region and
a C-terminal region consisting of 22 non-identical HEAT (Huntington,
elongation factor 3, protein phosphatase 2A, targets of rapamycin) re-
peats. UM-associated mutations in SF3B1 are found almost exclusively
in the fifth HEAT-repeat at codon position arginine (R) 625. In other
cancer types, such as breast cancer and leukemia, mutations in SF3B1
are more prevalent in the sixth and seventh HEAT-repeat at lysine re-
sidues K666 and K700, respectively. These lineage-specific mutations
can be explained by several factors, such as tissue-specific interaction
partners, the mutation rate of the gene and the activity of several
pathways in a specific tissue that might confer survival advantage
(Seiler et al., 2018a). However, since these residues are predicted to be
spatially close to one another, it is not surprising that these mutations
have a similar functional impact on transcription. RNA-sequencing data
from SF3B1-mutated UM and breast cancer samples show some unique
aberrant transcripts but the majority of the aberrant transcripts is ob-
served in both malignancies (unpublished data). Samples harboring a
mutation outside the HEAT-domains do not show aberrant splicing,
implying a different effector on splicing or no effect at all (Darman
et al., 2015).
SF3B1 is the most frequently mutated spliceosome gene in UM, but
mutations in U2AF1 and SRSF2 have also been described (Robertson
et al., 2017). U2AF1 and SRSF2 are both involved in the assembly of the
spliceosome and it has been shown that mutations in these genes pro-
duce alternative transcripts in hematological malignancies. Similar to
the SF3B1 gene, particular SRSF2 mutations are more prevalent: we
observed that 4 of the 5 SRSF2 in-frame deletions involve the same
protein residues (AA 92–99), indicating that this particular activity of
SRSF2 creates a specific effect on splicing, required in UM etiology (van
Poppelen et al., 2019). Whether the downstream effects of these mu-
tations are similar is unclear but these observations are intriguing and
are the subject of further research by us and others.
Most patients in our cohort with SF3B1-mutated UM eventually
developed metastasis, but have a longer disease-free survival than
BAP1-mutated UM, implying that SF3B1-mutated micro-metastases re-
main longer in their dormant state than BAP1-mutated micro-metas-
tases. In our own patient cohort, the effect of SF3B1 is probably masked
by the bulk of UM patients with BAP1 mutations, as we did not observe
a significant difference in prognosis for patients with or without a
SF3B1-mutated UM (Fig. 7A). However, in the disomy 3 group, SF3B1
mutations do show an association with a worse prognosis. The overall
survival curve of all UM, stratified by mutation subtype, confirms that
SF3B1-mutated UM are a distinct subclass associated with late metas-
tasis. It can also be observed that the overall survival can vary greatly
between SF3B1-mutated cases, as some develop metastases within 5
years whereas others after a decade (Fig. 7B) (Yavuzyigitoglu et al.,
2016b). What causes this difference in metastatic potential is not clear
and we did not find a specific segregation with the other well-known
clinical-pathological or genetic prognostic markers using principle
component analysis. However the number of patients in the early me-
tastasizing subgroups was small which could have prohibited a proper
analysis. We are in the process of collecting data of more patients with
SF3B1-mutated tumors to survey RNA expression and epigenetic dif-
ferences between these early and late metastasizing tumors, which
might help us understand these different effects of aberrant splicing on
metastatic risk.
Fig. 6. Splicing of pre-mRNA into mature mRNA. Wildtype SF3B1 binds to
the branchpoint (BP) of the pre-mRNA, which is usually an adenosine located
~25 nt upstream of the 3′ splice site (3′ ss). This allows a correct assembly of
the spliceosome on the pre-mRNA, resulting in mature mRNA and a canonical
protein. Whereas mutant SF3B1 recognizes an alternative BP (BP′), resulting in
mis-spliced mRNA. This mis-spliced mRNA can be translated into an aberrant
protein or degraded by nonsense-mediated RNA decay, resulting in down-
regulation of the RNA and protein. Reproduced with permission from Darman
et al. (2015), via Copyright Clearance Center.
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2.4. EIF1AX plays an important role in the initiation of translation
The EIF1AX gene is mutated in approximately 20% of UM and is
involved in the initiation of gene translation in eukaryotic cells (Martin
et al., 2013). Ribosomes bind the 5’ end of the mRNA in a relatively
unstable state, which allows scanning of the mRNA for the start codon.
Several eukaryotic initiation factors (EIFs) support the ribosome in this
process and subsequently stabilize the ribosome once it reaches a start
codon. EIF1A consists of a globular domain and two unstructured tails,
the N- and C-terminal tail, which are involved in the scanning of the
mRNA and the accurate recognition of the start codon.
UM patients harboring only an EIF1AX mutation (in addition to a
GNAQ or GNA11 mutation) hardly metastasize; in our cohort, none of
the patients with a pure EIF1AX mutation developed metastases: the
only EIF1AX-mutated patient who developed metastases had a con-
current BAP1 mutation (Fig. 7B). Remarkably, UM-associated muta-
tions in EIF1AX -indicated in Fig. 8 by the red dots-occur exclusively in
the N-terminal tail of the protein, a highly conserved region in eu-
karyotes. Mutations in the N-terminal tail inhibit the scanning process
by stabilizing the ribosome. This promotes the utilization of less op-
timal start codons and thereby alters gene expression in UM (Martin-
Marcos et al., 2017). Experiments in yeast show that EIF1A mutations
alter the relative use of start codons in mRNA encoded by tumor sup-
pressor genes or oncogenes. Immunohistochemical staining of EIF1AX
in samples harboring a mutation showed a positive staining throughout
the cytoplasm of the cell, showing that mutations in the EIF1AX gene do
not cause loss of the protein (Martin et al., 2013). EIF1AX mutations
have also been observed in other cancer types, such as breast cancer,
prostate cancer, adenocarcinoma and glioma (indicated in Fig. 8 by the
grey dots) (Tate et al., 2019). Surprisingly, these mutations are found
throughout the entire protein-coding DNA, as opposed to UM, where
mutations are only observed in the N-terminal tail. This raises the
question if the N-terminal region of EIF1AX executes specific functions
or engages with specific binding partners in UM. Change of function
mutations in the EIF1AX gene might make melanocytes more malignant
and stimulate their division, but not enough to initiate metastasis.
Whether UM cells do not spread at all or whether micro-metastases are
present in distant organs but remain dormant, is unknown.
3. Chromosomal abnormalities and RNA expression in UM
UM progression involves several chromosomal gains and losses.
Chromosome 8q gain and complete loss of chromosome 3 frequently
occur in high-risk UM, whereas low metastatic risk UM carry two copies
of chromosome 3 and often show gains of chromosome 6p (UM type A)
and distal 8q (UM category B) (Damato et al., 2011; Jager et al., 2018;
Prescher et al., 1996; van den Bosch et al., 2012). Thirty percent of UM
patients also have a deletion of chromosome 1p, which is associated
with a higher metastatic risk (Kilic et al., 2005). Aberrations on other
chromosomes have been observed, but are less frequent and show no
correlation to metastatic risk. Cytogenetic analyses are useful but very
time and labor consuming. Culturing UM tumor cells is hampered by
overgrowth of fibroblasts and only short time cultures can be used to
obtain an accurate karyotype. Nowadays, a Single Nucleotide Poly-
morphism (SNP) array technology is used to determine copy number
variations (CNV) in tumor specimens. Apart from the observation that
Fig. 7. Disease-free survival of UM patients. A) Kaplan-Meier curve showing the disease-free survival of the SF3B1mut UM in the overall or disomy 3 group. B) In
the overall survival curve containing all UM; it can be observed that every mutation status corresponds with a distinct survival pattern. Reproduced with permission
from Yavuzyigitoglu et al. (2016b) via Copyright Clearance Center.
Fig. 8. EIF1AX mutations. Malignant mutations
in the EIF1AX protein observed in UM (red) and
other cancer types (grey). All observed mutations
are in-frame mutations (Tate et al., 2019).
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CNV analysis as such is an independent prognostic test and does con-
tribute to prognostication models (Drabarek et al., 2019; Eleuteri et al.,
2012), we have observed earlier intriguing differences between these
CNVs in metastasizing UM which did urge us to go back to the results
obtained with karyotype analysis. We noticed that whereas BAP1-mu-
tated tumors did harbor in general a few whole chromosome anomalies
resulting in isochromosome formation (e.g. (i)8q or (i)6p), in SF3B1-
mutated tumors smaller gain or losses of the terminal parts of chro-
mosome 6p and 8q are more prevalent (Yavuzyigitoglu et al., 2017).
Whether this is a consequence of the underlying BAP1 or SF3B1 mu-
tation causing a different route to generate these chromosomal aber-
rations or that the resulting genetic changes sort out the most optimal
effect in combination with the specific mutated gene, is not clear. Most,
if not all UM, present with both the mutation and the matching set of
CNVs, but we occasionally observe these mutations without the corre-
sponding CNV patterns or vice versa. A scrutinized genetic survey of
these rare cases, preferably with –when available- also the subsequent
metastatic tissues may shed more light on this causality dilemma. Al-
ternatively, site-directed mutagenesis of these genes using CRISPR/
Cas9 in melanocytic cells could help us to answer the chicken and egg
story and analyze other intriguing differences regarding the altered
pathways and route towards metastasis between BAP1 or SF3B1-mu-
tated tumors.
Nevertheless, these chromosomal abnormalities contribute to the
development of UM by altering gene expression. Specific gene expres-
sion profiles (GEP) are associated with low metastatic risk (class 1a),
intermediate metastatic risk (class 1b) or high metastatic risk (class 2)
(Field et al., 2016; Onken et al., 2004; Tschentscher et al., 2003;
Zuidervaart et al., 2003). Interestingly, we described in a previous
publication that differential expression only partially correlated with
chromosomal abnormalities (Fig. 9). For example, a large part of the
genes located on chromosome 3p were significantly downregulated in
class 2 UM, whereas genes located on chromosome 3q were not (van
Gils et al., 2008). In addition, parts of chromosome 8q and 6q showed
upregulation. This indicates that other mechanisms, such as methyla-
tion, might compensate for chromosomal abnormalities.
The oncogene MYC is located in the frequently amplified chromo-
some 8q24 region. Several analyses show that the presence of extra
copies of chromosome 8 is associated with a worse prognosis (Cassoux
et al., 2014; Damato et al., 2011; Dogrusoz et al., 2017; Versluis et al.,
2015). Although MYC signaling has been shown to be involved in UM
development, no direct association has been observed between MYC
expression and metastatic death (Robertson et al., 2017). Expression of
the adjacently-located long non-coding RNA PVT1 (plasmacytoma
variant translocation gene) does show a direct association with me-
tastasis. This indicates that gene expression regulation is complex and
that other processes, in addition to copy number status, are involved in
regulating expression levels. PVT1 is often amplified in several cancer
types and acts as an oncogene by regulating transcriptional activity and
acting as a miRNA sponge by binding to complementary miRNAs,
thereby preventing the miRNAs from exerting their role in gene ex-
pression. Another oncogene located on the amplified 8q region is de-
velopment and differentiation enhancing factor 1 (DDEF). High-risk UM
show higher DDEF expression than low-risk UM. DDEF regulates the
remodeling of the cytoskeleton, which is necessary for cell motility.
Overexpression of DDEF in low-risk UM cells increases their motility,
suggesting that upregulation of DDEF contributes to the invasive phe-
notype of high-risk UM. However, most of these studies do not dis-
criminate between SF3B1 and BAP1-mutated tumors, so these ob-
servations might not be valid for the often small 8q amplified regions of
SF3B1-mutated tumors. Hence, repeating these analyses in well-defined
UM subgroups based on genetic changes in the secondary driver genes
might result in a different set of classifier genes. Furthermore, ampli-
fication of an isochromosome 8q (8q gain in combination with 8p loss),
as seen frequently in BAP1-mutated tumors is also present in other
tumor types. In a recent study on hepatocellular carcinoma performed
by The Cancer Genome Atlas (TCGA) network, 14 of 23 BAP1-mutated
samples did show signs of isochromosome 8q, suggesting a similar
common and perhaps more universal underlying genetic mechanism
(Cancer Genome Atlas Research Network. Electronic address and
Cancer Genome Atlas Research, 2017). It would be interesting to de-
termine whether other SF3B1-mutated tumors harbor similar
SF3B1–CNV patterns in addition to the observed overlap in altered
expressed RNAs.
Gene expression can also be used to predict disease-free survival of
UM patients. Unsupervised clustering of primary UM based on mRNA
Fig. 9. Differential gene expression between class 1 and class 2 UM. Several chromosomal regions contain differentially expressed genes identified by a locally
adaptive statistical procedure (LAP)-analysis. White bars indicate locations of the microarray-probes, whereas red (upregulation) or green (downregulation) indicate
a differentially expressed gene. Adapted from van Gils et al. (2008).
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expression shows two distinct classes as shown by Onken et al. (2004).
Class 1 consists of EIF1AX and SF3B1-mutated UM that show the
transcriptome of a differentiated melanocyte, whereas class 2 contains
monosomy 3/BAP1-mutated tumors characterized by a stem cell-like
expression profile. Functional annotation of these differentially-ex-
pressed genes revealed involvement in development, cell communica-
tion, cell growth, cell motility and apoptosis. Interestingly, most of the
identified developmental genes are known to be implicated in neural
crest development (Onken et al., 2004).
TCGA contains the expression data of 80 primary UM. Monosomy 3
TCGA samples showed increased transcription of MAPK, AKT and the
transcription factors FOXA1 and FOXM1, indicating increased pro-
liferation in this group (Robertson et al., 2017). Several long non-
coding RNAs were found to be higher expressed in monosomy 3 sam-
ples, such as the aforementioned PVT1 gene, as well as the oncogenes
CYTOR and BANCR. The expression of multiple immunological genes
was also significantly elevated in the poor prognosis clusters. This in-
dicates an activation of the immune system, which is in contrast to what
has been observed in other cancer types, where an activated immune
system is typically seen in tumors with low metastatic risk. An asso-
ciation between monosomy 3 and an inflammatory phenotype has been
described previously (Maat et al., 2008). An important difference may
be that UM metastasizes hematogeneously, and that the presence of
infiltrating macrophages contributes to intratumoral vessel growth
(Bronkhorst et al., 2011; Brouwer et al., 2019; Jager et al., 2011; Ly
et al., 2010).
Within the monosomy 3 TCGA samples, two separate clusters were
observed, categories C and D (Jager et al., 2018; Robertson et al.,
2017). Surprisingly, one cluster showed an activation of the DNA da-
mage response (DDR) pathway, which, however is not reflected in the
mutational load of UM. MYC signaling and HIF1a were also upregulated
in this cluster, which is consistent with aberrant BAP1 expression. The
other cluster is characterized by elevated levels of MAPK and AKT, two
effectors of the Gα11/Q pathway. This implies that BAP1 loss may
enhance the effect of oncogenic GNAQ and GNA11.
4. UM metastases
Most UM research focuses on primary UM, although the metastases
cause death in UM patients and not the primary tumor. Metastatic
outgrowth of a tumor is a complicated, multi-step process that is often
difficult to unravel. Only a few UM patients with metastases undergo
liver resection, and diagnostic biopsies usually do not provide sufficient
material for additional research. Moreover, metastases samples can
contain a mixture of UM cells, admixed reactive cells as well as hepa-
tocytes, making a proper description of the genomic profile of UM
metastases challenging.
4.1. Metastatic spread of UM
The metastatic capacity of cancer cells is mainly determined by the
interaction with the microenvironment. In order to allow UM cells to
grow in distant organs, several steps have to be taken; they must lose
contact with neighboring cells, home and survive in the host organ,
become established and finally also be able to grow into macro-me-
tastases (Lambert et al., 2017). Therefore, it could be hypothesized that
UM cells need to acquire several additional genetic aberrancies in order
to successfully grow in distant organs.
In 1882, the ophthalmologist Ernst Fuchs described the predis-
position of uveal melanoma to metastasize to the liver and postulated
an organ-specific predisposition for metastases (Fuchs, 1882). Seven
years later, Paget formulated the famous Seed and Soil hypothesis
(Paget, 1889) which suggests that metastasis is not random and cancer
cells (the seeds) show a preference when metastasizing to distant organs
(the soil). Since the large majority of UM metastasize to the liver, it
could be implied that there is a favorable microenvironment in the liver
for UM cells. Whether the primary tumor stimulates this micro-
environment by promoting the development of pre-metastatic niches
remains unclear. Unraveling which factors in the liver contribute to this
favorable microenvironment might provide us with possible therapeutic
targets. One factor that is thought to play an important role in creating
a pre-metastatic niche in specific organs are exosomes. These small
(~100 nm) lipid bilayer-delimited vesicles are released from cells and
carry several functional biomolecules that can be transferred to re-
cipient cells. A specific repertoire of integrines on the exosome-surface
dictates the adhesion of exosomes to specific cell types; Hoshino et al.
have shown that tumor-derived exosomes preferentially interact with
cells at the future metastatic site (Hoshino et al., 2015). After these
exosomes are taken up by the target cells, several signaling pathways
and inflammatory responses are initiated which are necessary to com-
plete the development of the pre-metastatic niche (Liu and Cao, 2016).
Since a study by Angi et al. has shown that primary cultured UM cells
secrete almost half of their secreted proteins via exosomes, one may
speculate that exosomes play a role in metastasis formation in UM (Angi
et al., 2016).
UM patients who have undergone successful treatment of the pri-
mary tumor still develop metastases. This implies that UM cells have
already spread into the circulation before the primary tumor was di-
agnosed and treated. A study by Eskelin et al. calculated tumor dou-
bling times for UM and showed that primary UM metastasize already
several years before treatment (Eskelin et al., 2000). With this in mind,
one would expect that circulating tumor cells (CTCs) could be detected
at time of diagnosis. However, CTCs are mainly detected in blood of
patients with metastatic UM, whereas patients with primary UM often
show no CTCs (Beasley et al., 2018). Whether this is due to the low
number of CTCs in blood at the time of diagnosis or the seeding of CTCs
by metastatic lesions is unknown. Isolating these rare CTCs both at
diagnosis and during the metastatic phase could aid our understanding
of the metastatic process in UM. Another promising biomarker that
could identify dissemination of UM is cell-free DNA (cfDNA). CfDNA are
small fragments of DNA that are released in the circulation by (tumor)
cells and are present in increased amount in cancer patients. Several
studies have showed that GNAQ and GNA11-mutations could be de-
tected in cfDNA from metastatic UM patients and that their presence
showed an association with metastases-volume and overall survival
(Beasley et al., 2018; Bidard et al., 2014; Metz et al., 2013).
4.2. Chromosomal alterations in UM metastases
A wide spectrum of chromosomal alterations can be identified in
UM metastases, such as gain of 8q, 6q, 1q and alterations in chromo-
some 3. These chromosomal alterations are also commonly found in
primary UM, however, the frequencies are different (McCarthy et al.,
2016). UM metastases showed more copies of 8q than the corre-
sponding primary UM (Shain et al., 2019). Given this high prevalence
of 8q amplifications in UM metastases, it could be hypothesized that the
8q region contains gene(s) that potentially promote metastasis. How-
ever, further investigation is necessary in order to determine whether
upregulation of oncogenes such asMYC and PTP4A3 have a direct effect
on metastasis, or that this is just a consequence of extra copies of
chromosomal region 8q. As expected, the majority of UM metastases
contained alterations in chromosome 3. Whereas primary UM mainly
show monosomy 3, UM metastases frequently showed isodisomy 3 and
large regions of homozygosity (McCarthy et al., 2016; Rodrigues et al.,
2019). Monosomy 3 at first stimulates tumor progression through BAP1
inactivation; however, haploinsufficiency of some chromosome 3 genes
could result in a reduced expression of genes such as MITF, MBD4 and
CTNNB1 and thereby limit UM progression (Onken et al., 2004; van Gils
et al., 2008). In response to this limitation, duplication of chromosome
3 could be a compensating mechanism in metastasizing UM cells.
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4.3. Mutational analysis in UM metastases
As described in the introduction, UM shows a remarkable low mu-
tational burden compared to other malignancies. Rodrigues et al. se-
quenced 15 UM trio's (germline, primary UM and UM metastases) and
did not observe a significant increase in SNVs between primary UM and
its metastases (median 13 SNVs vs 16 SNVs) (Rodrigues et al., 2019).
All UM metastases contained a mutually exclusive GNAQ or GNA11
mutation that matched with the primary UM, confirming that these
mutations arise early in the development of the disease. Interestingly,
Shain et al. also observed LOH of mutant GNAQ in multiple metastases
samples, suggesting that GNAQ-mutated UM require a second hit later
in UM progression. LOH of mutant GNAQ shifts the allelic balance to-
wards mutant GNAQ, which activates the GαQ signaling even further,
thus allowing cells to become fully malignant (Shain et al., 2019). This
corresponds with previous studies suggesting that GNA11-mutations
are more potent oncogenes, since an over-representation of mutations
in GNA11 was observed in UM metastases (Griewank et al., 2014).
Secondary driver mutations in BAP1 and SF3B1 were observed in high
frequencies in UM metastases as well, indicating early occurrence.
Surprisingly, additional mutations in new oncogenes were also ob-
served in UM metastases, which however, occurred in much lower
frequencies than the secondary driver mutations. This indicates that
these tertiary driver mutations occur later in UM progression, after
mutational activation of BAP1 and SF3B1. Tertiary driver mutations
were found in oncogenes, such as PTEN, EZH2, CDKN2A, TP53
(Rodrigues et al., 2019; Shain et al., 2019). These newly-identified
mutations might offer new opportunities in UM therapeutics. However,
it is still early for the field to develop therapies targeting these genes.
Firstly, it remains unclear to what extent each of these mutations
contributes to the malignant phenotype. Secondly, novel targeted
treatment may possibly only have an effect on metastatic UM subclones
harboring particular actionable mutations.
5. Therapeutic options
We have gained considerable insight into the genetic background of
UM, but this has not yet resulted in successful treatments of metastatic
UM. Treatment of metastatic UM with classic chemotherapy has been
disappointing, with low response rates (Carvajal et al., 2014b;
Chattopadhyay et al., 2016). Over the past 35 years, survival of patients
with metastatic UM has not improved (Rantala et al., 2019). However,
now that we know the genes and the pathways they might be involved
in, we can start developing new therapeutic modalities for UM.
5.1. Targeting the Gα11/Q pathway
Since the majority of UM contain mutations that deregulate the
Gα11/q pathway, drugs targeting this pathway might be effective in the
majority of UM, regardless of their further mutational background.
Inhibiting GNAQ and GNA11 themselves might be difficult, because of
high GTP levels in the cytoplasm. Several studies have therefore fo-
cused on interfering with the critical downstream effectors, such as
MAPK, PKC, PI3K and AKT signaling. Clinical trials with the MEK1/2
inhibitor selumetinib resulted in promising preliminary results
(Carvajal et al., 2014a). UM patients treated with selumetinib had an
improved progression-free survival of up to 15 weeks, compared to
patients treated with chemotherapy. Unfortunately, selumetinib did not
improve overall survival in UM patients. This indicates that selumetinib
can inhibit metastatic growth only for a limited time: once the tumor
acquires resistance to MEK inhibition, it grows even more aggressively
than non-treated metastatic tumors. A combination of the chemother-
apeutic drug dacarbazine and selumetinib did not give improvement in
survival (Carvajal et al., 2018). Similar results were obtained with the
MEK inhibitor trametinib and the Akt inhibitor GSK795: no improved
survival rate was observed in 40 metastatic UM patients (Shoushtari
et al., 2016).
These disappointing results could be explained by acquired re-
sistance, which also causes CM patients to become resistant to the BRAF
inhibitor vemurafenib (Nazarian et al., 2010). Another reason for this
limited response could be that these inhibitors act far downstream of
oncogenic GNAQ and GNA11. As shown by Mouti et al., progression of
UM in zebrafish is dependent on YAP activation, rather than activated
extracellular signal-regulated kinases (ERK). Only a subset of the ma-
lignant uveal melanocytes showed activation of ERK, while knockdown
of GNAQ or PLCB4 did not affect the levels of activated ERK, suggesting
that MAPK signaling only partially contributes to the development and
maintenance of UM (Mouti et al., 2016). Inhibiting only one arm of an
oncogenic network is likely less efficient than interfering with nodes
that act closer to GNAQ and GNA11, such as ARF6.
ARF6 regulates multiple downstream signaling pathways and might
therefore be a more suitable target for treatment of UM. Knockdown of
ARF6 induces the re-localization of GNAQ and GNA11 from the cyto-
plasm to the plasma membrane, resulting in a decrease of all Gα11/q
-mediated pathways. Yoo et al. showed that inhibition of ARF6 in the
GNAQ- and SF3B1-mutated UM cell line, Mel 202, resulted in a lower
tumor incidence and size when injected into immune-compromised
mice (Yoo et al., 2016). A significant reduction in the levels of down-
stream activated ERK, RAC/RHO, p38, JNK and C-JUN was observed as
well. Treating cells and xenograft mouse models with NAV-2729, a
direct inhibitor of ARF6, resulted in similar results as the knockdown
experiments. Until now, the results have been promising and no toxicity
was observed; however, this treatment is not yet FDA-approved and
additional studies have to be performed to investigate whether phar-
macological inhibition of ARF6 is an effective treatment for UM.
Other targets for UM treatment could be PLCB4 and YAP. YAP can
be successfully inhibited by the well-tolerated compound verteporfin.
Treatment of xenograft mouse models with this drug showed a reduc-
tion in UM growth (Yu et al., 2014b). However, these compounds too
only target one arm of the oncogenic Gα11/q network and it is there-
fore likely that they will only show a limited effect unless they are used
in combination with another drug.
5.2. HDAC inhibitors to reverse the effect of BAP1 loss
Several studies have described histone deacetylase inhibitors
(HDACI) as promising anti-cancer drugs. HDACIs interfere with HDACs,
which are frequently upregulated in cancer (Halkidou et al., 2004; Song
et al., 2005; Zhang et al., 2005). These HDACs remove acetyl groups
from histones, which changes the structure and accessibility of chro-
matin and thereby affects gene expression (Li et al., 2010). UM cell lines
or xenograft models treated with HDACI show a reduced proliferation
and an induced cell cycle arrest. A study by Landreville and colleagues
(Landreville et al., 2012) described that BAP1-deficient cells have an
increased sensitivity for HDACI. HDACIs initiated morphologic and
transcriptomic changes consistent with melanocyte differentiation and
reduced proliferation through G1 cell cycle arrest. BAP1-deficient cells
might be more sensitive to HDAC inhibition because of their increased
H2A ubiquitination. It has been shown that distinct histone modifica-
tions act together to regulate chromatin structure and gene expression:
for example, the deubiqituitinase enzyme H2A-DUB not only regulates
deubiquitination of histones, but also acetylation (Zhu et al., 2007).
Interfering with the acetylation of histones in BAP1-deficient UM might
reverse the biochemical deficit caused by BAP1 loss by shifting the cell
to a less aggressive, more differentiated state. HDACIs could therefore
prolong survival of UM patients by keeping micro-metastases in a
quiescent, differentiated state.
5.3. Spliceosome inhibitors
SF3B1-mutated UM require a different approach. As mentioned
before, tumors with an SF3B1 mutation show aberrant splicing of pre-
K.N. Smit, et al. Progress in Retinal and Eye Research xxx (xxxx) xxxx
9
mRNA resulting in an increased rate of transcripts containing pre-
mature termination codons. Mutations in splicing factors always occur
in a heterozygous state and have never been observed to coincide with
another splicing-factor mutation. The spliceosome is essential for sur-
vival and cancer cells require wildtype splicing to survive. Inhibiting
the spliceosome in cancer cells with spliceosome inhibitors has shown
exciting results in several different malignancies and might therefore
also be a promising treatment for UM.
Several components have been identified that are able to success-
fully inhibit the spliceosome assembly at an early stage, such as sude-
mycin (Fan et al., 2011), E7107 (Kotake et al., 2007) and spliceostatin
A (Kaida et al., 2007). E7107 and spliceostatin A bind non-covalently to
SF3B1 and thereby prevent exposure of the branchpoint-binding region
of U2 snRNP. This results in defective formation of the spliceosome
early in the splicing process. Mutations in the SF3B1 gene result in
resistance to E7107, as shown by long term treatment of human col-
orectal cancer cell lines with E7107 (Yokoi et al., 2011), indicating that
only wildtype (WT) SF3B1 is affected. Since SF3B1-mutated UM require
wildtype splicing in order to survive, interference of WT SF3B1 by
E7107 will result in cell death.
In vivo treatment of isogenic murine myeloid leukemias that harbor
an SRSF2 mutation with E7107, reduced the leukemic burden by in-
ducing preferential cell death of cells bearing an SRSF2 mutation (Lee
et al., 2016). Inhibition with this compound showed the same effects as
RNAi-mediated silencing of SF3B1, such as an accumulation of un-
spliced mRNA in the nucleus. A subset of this unspliced mRNA leaked
into the cytoplasm, which resulted in the production of aberrant pro-
teins, including an unusually stable form of the cell cycle inhibitor p27
(Kotake et al., 2007). Unfortunately, clinical trials with E7107 in pa-
tients with metastatic solid cancer had to be suspended due to an un-
expected side effect in bilateral optic neuritis, resulting in loss of vision.
However, in most patients the drug was well tolerated and inhibition of
splicing was observed (Eskens et al., 2013; Hong et al., 2014). Addi-
tional compound screens will be necessary to identify spliceosome in-
hibitors that act on the spliceosome assembly at a later stage. Recently,
a phase 1 trial was started with the new spliceosome inhibitor H3B-
8800 (Seiler et al., 2018b).
While targeting the spliceosome will probably have most potential
in SF3B1-mutated UM, it might also be beneficial to treat BAP1-mutated
UM with these compounds, as it has been shown that cancer cells with
an increased MYC activity might also be more vulnerable to spliceo-
some inhibition (Hsu et al., 2015). Since a subset of the BAP1-mutated
tumors show an upregulation of MYC, treatment of these tumors with
spliceosome inhibitors might be a promising option.
A possible problem with spliceosome-inhibitors might be their lack
of specificity. Another method to alter splicing in cells is through oli-
gonucleotides. Oligonucleotides bind to RNA in a sequence-specific
manner and prevent interaction between the spliceosome and pre-
mRNA by steric hindrance. Aberrantly-spliced genes, that contribute
significantly to the malignant phenotype of UM, can thereby be speci-
fically targeted and inhibited. Oligonucleotides have been shown to
regulate the presence of aberrant splice variants and restore the pro-
duction of essential proteins (McClorey and Wood, 2015). Un-
fortunately, no oligonucleotide-based treatment has yet been approved
for the treatment of cancer patients.
5.4. Immunotherapy in UM
Metastasis can arise several years after successful removal of the
primary tumor. This long latency period can be explained by the pre-
sence of dormant UM cells, and dormancy may be due to im-
munological inhibition. Once a cancer cell is able to overcome the
immune response, micro-metastases can start to proliferate, which will
result in a fatal outcome.
A new, exciting area of cancer drug development is immunotherapy.
One example of immunotherapy is the use of monoclonal antibodies
against CTLA-4, PD-1 and PD-L1. CTLA-4 and PD-L1 act as natural
immune checkpoints in T cells, to tune down and thereby avoid ex-
aggerated immune responses. It has been shown that cancer cells sup-
press immune responses by upregulating the ligand PD-L1. The mono-
clonal antibodies used in immunotherapy block the checkpoints and
subsequently unblock and thus activate T cells, which results in the
removal of cancer cells. Many of these monoclonal antibodies have
already been approved for clinical use, such as nivolumab targeting PD-
1. Immunotherapy treatment of advanced melanoma, lung cancer and
renal cancer patients showed remission and in some cases even eradi-
cated metastatic disease. Unfortunately, these antibodies show only
limited activity in UM patients (van der Kooij et al., 2017; Wierenga
et al., 2019; Zimmer et al., 2015). Dual immune-checkpoint blocking
resulted in a response rate of 38% in CM, but no response was observed
in UM patients (Kirchberger et al., 2018). These disappointing results
cannot solely be explained by the fact that UM do not express PD-L1,
since two studies show heterogeneous expression of PD-L1 (> 5% po-
sitivity) in approximately 50% of the UM (Fig. 10) (Wierenga et al.,
2019; Zoroquiain et al., 2018). However, a potentially more promising
strategy would be to inhibit checkpoints that have been shown to be
consistently highly upregulated in metastatic UM, such as indoleamine-
pyrrole 2,3-dioxygenase (IDO) and T cell immunoreceptor with Ig and
ITIM domains (TIGIT) (Robertson et al., 2017; Stalhammar et al.,
2019b). Interestingly, Rodrigues et al. describe an unexpected high
Fig. 10. Heterogenous PD-L1 expression in
primary UM. The lowest magnification (0.3x)
shows the flat choroidal tumor, whereas the
medium magnification (1.4×) shows diffuse
membranous expression of PD-L1. This is con-
firmed at higher magnifications; the top right
and lower right picture (20× and 40x respec-
tively) show positive membranous PD-L1 ex-
pression in UM cells (small arrowheads), posi-
tively-stained retinal pigmented epithelium cells
(large arrowheads) and tumor-infiltrating mac-
rophages (small arrows). Reproduced with per-
mission from Zoroquiain et al. (2018) via
Copyright Clearance Center.
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sensitivity to the PD-1 inhibitor pembrolizumab in one UM patient
(Rodrigues et al., 2018). DNA sequencing identified a germline muta-
tion in MBD4, a gene located on chromosome 3 and involved in base
excision repair. Mutations in this gene result in an unusual high mu-
tational load, thereby sensitizing the tumor to PD-1 inhibition. A similar
UM patient was recently described (Johansson et al., 2019), while
within the TCGA-dataset, two other UM patients with MBD4 mutations
were identified, indicating that a small fraction of the UM patients
could directly profit from PD1-inhibition.
A more classic approach to immunotherapy is inducing an immune
response by making use of activated dendritic cells (DCs). A colla-
borative study in The Netherlands by Bol et al. treated UM patients with
autologous DCs loaded with antigens derived from gp100 or tyrosinase,
two melanocyte-specific proteins (Bol et al., 2016). No severe toxicities
were observed after the vaccinations and 74% (n=17) of the patients
showed the presence of tumor-specific T cells after DC vaccination,
indicating an activation of the immune system. These patients showed a
significantly longer disease-free and overall survival than patients that
did not show an immune response (58 months vs 45 months respec-
tively) (Fig. 11). However, no significant difference in the overall sur-
vival rate was observed compared to the control group (Bol et al.,
2016). A new approach uses a novel molecule, tebentafusp, to initiate
an immune response in UM patients. Tebentafusp acts as a bridge be-
tween UM and cytotoxic T cells and thereby ultimately results in T-cell
activation and subsequent killing of UM cells (Damato et al., 2019;
Komatsubara and Carvajal, 2017). Preliminary results indicate that
biopsies, which were taken after the injection, confirmed the influx of
lymphocytes and an increase in PD-L1 expression.
Still, the results obtained from widely used immunotherapy un-
fortunately present less promising results in UM patients than in CM
patients. As the eye is an immune-privileged site, immune responses
may not develop as easily as in other locations, and may even be in-
hibited actively (Niederkorn, 2009). In most cancer types, immune in-
filtration is associated with good prognosis and sensitivity to im-
munotherapy. However, especially the prognostically infaust
monosomy 3 UM show a dense immune infiltrate and increased HLA
Class I expression (Bronkhorst et al., 2012; de Lange et al., 2015; Jager
et al., 2011). This different response rates could be explained by the
presence of immunosuppressive cells, such as regulatory T cells and
macrophages, which dampen the immune response. A study of low risk
and high risk tumors indicated that extra copies of chromosome 8q
were associated with influx of macrophages, while loss of BAP1 was
linked to higher numbers of T cells (Bronkhorst et al., 2012; Gezgin
et al., 2017). These data show that genetic changes are related to the
development of the inflammatory phenotype in UM, but they do not
explain why the immune system is so unresponsive in most patients.
However, all these results imply that future immunotherapy agents
should mainly focus on overcoming the immune suppression in UM. By
determining the precise immune landscape in every tumor, we might be
able to predict which UM would be sensitive to immunotherapy. An-
other factor that could explain the disappointing response rate to im-
munotherapy is the low mutational load of UM cells. As previously
described, CM show a high mutational burden which correlates with a
plethora of neo-antigens and thus renders them particularly suitable for
immunotherapy. However, SF3B1-mutated UM could very well be more
sensitive to immunotherapy if this is directed against the proteins
produced by aberrant splicing. Mass spectrometry analysis of the pro-
teome secreted by SF3B1-mutated UM could identify and characterize
these aberrant proteins.
These aforementioned treatments can be given systemically in order
to remove any metastases in distant organs; however they can also be
given locally to UM patients with liver metastases by isolated hepatic
perfusion (IHP). In case metastatic disease is confined to the liver, the
liver can be isolated from the systemic circulation, which allows a much
higher concentration of therapeutics to be used. Fifty to seventy-five
percent of metastatic UM patients responded to IHP with the che-
motherapeutic agent melphalan. The most common adverse effects
were hematological events – such as thrombocytopenia, anemia, and
neutropenia – which were clinically manageable, indicating that IHP
with melphalan could be a promising treatment for UM patients with
liver metastasis (Artzner et al., 2019; Meijer et al., 2019; Vogel et al.,
2017). Currently IHP is performed for established metastatic disease,
but future drugs with less side-effects might allow targeted adjuvant
treatment in high-risk UM patients (Olofsson et al., 2014).
6. Future directions and conclusions
Even though our understanding of UM has advanced in the last
decade, UM remains one of the very few malignancies for which there is
no treatment available for metastatic disease. In recent years, there has
been a tendency to transpose treatments shown to be effective in CM to
UM, such as immunotherapy and MEK-inhibitors. However, as de-
scribed in multiple studies, the biological behavior of these two ma-
lignancies is completely different and therefore they require a different
approach. A better understanding of the complex genetic and im-
munologic background of UM will allow a more personalized approach
which is necessary for effective treatment. Treatments targeting onco-
genic GNAQ and GNA11 signaling could be applied to all UM patients,
although it remains unclear if this will be sufficient for effective UM
treatment. GNAQ and GNA11 are relatively weak oncoproteins and can
only become truly malignant when combined with co-mutations in
secondary driver genes. Therefore, additional research into agents tar-
geting these deregulated processes, such as spliceosome inhibitors and
HDAC inhibitors, is necessary.
The genetic background could also play a role in the treatment
outcome. SF3B1-mutated tumors could benefit from different ther-
apeutic agents than BAP1-mutated tumors. This might require a more
personalized approach, where the genetic background of each UM pa-
tient is investigated in the diagnostic setting and determines the best
treatment option (Fig. 12). In the case of an EIF1AX-mutated UM, local
treatment of the primary tumor could already be sufficient. However,
SF3B1 and BAP1-mutated UM will require a more rigorous treatment
protocol. For these patients it is known that in many cases micro-me-
tastases are already present at the time of diagnosis, meaning that
Fig. 11. Survival of high risk UM patients after
dendritic cell treatment. Kaplan-Meier curve
showing the disease-free survival (A) and overall
survival (B) in correlation with the presence of
tumor antigen-specific T cells after receiving den-
dritic cell vaccination. Reproduced with permission
from Bol et al. (2016), via Copyright Clearance
Center.
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besides treatment of the primary tumor, the dormant micro-metastases
have to be targeted as well to improve overall patient survival. We
therefore hypothesize that a combinatorial treatment approach in
which local treatment of the primary tumor is combined with systemic
treatment targeting the micro-metastases in high-risk cases would have
the most potential in UM therapeutics. However, it remains con-
troversial which specific characteristics are necessary to define high-
risk UM patients, since different research groups use different prog-
nostic parameters. In order to synchronize UM prognostication and
treatment, a universal prognostication model using a combination of
clinical, histological and genetic parameters should be considered to
reliably identify high-risk UM patients (Drabarek et al., 2019; Eleuteri
et al., 2012; Vaquero-Garcia et al., 2017). A number of important
questions still remain open and research into these questions will dra-
matically aid the development of treatments for metastatic UM: does
the entire GNAQ and GNA11-signaling network contribute to the de-
velopment and progression of UM or is it only one arm of the network?
Which gene on chromosome 8q plays a role in the development of
metastases? Which functions of the BAP1 protein contribute mostly to
the aggressive phenotype observed in UM? What is the role of macro-
phages versus infiltrating T lymphocytes in high risk tumors, or are
both only bystanders? And what stimulates dormant UM micro-metas-
tases in the liver to suddenly proliferate and give rise to fatal metastatic
foci? The complexity and rarity of this type of cancer has made research
into this malignancy difficult, but the recent progress in our under-
standing of UM will bring us step-by-step closer to effective treatments.
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